Additionally, the appearance of established therapeutic targets such as HER2 and ER on CTCs not present on the primary tumor is of considerable clinical importance, and the results of ongoing HER2-targeting trials are awaited with interest. The gene discussed is ERBB2; the disease is neoplasm.